Accessibility StatementSkip Navigation -- New North American logistics center will provide expanded distribution for CollPlant's rhCollagen and BioInks as well as enable logistical efficiencies -- REHOVOT, Israel, Oct. 27, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen), today announced the expansion of its distribution footprint into N ...

Below we will discuss about a company that started as a biotech startup that had the vision of detecting cancer early but now is evolving into a clinically validated enterpriseMr. Mavroudis is a professional portfolio manager specializing in institutional and private portfolios. He focuses on risk management, which is accompanied by in-depth financial market analysis (fundamental, macro and technical) to control the risk undertaken by the portfolios. He invests in all financial instruments globally (stocks, ...

Tonmya demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT studyTreatment was well tolerated with minimal effects on weight or blood pressure and discontinuation rate of 19% vs. placebo of 20.8% Data support the potential of Tonmya as a well-tolerated, centrally acting, non-opioid analgesic and therapeutic option for adults with fibromyalgia CHATHAM, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “ ...

Accessibility StatementSkip Navigation HOLON, Israel, Oct. 27, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical- stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that the Company will release its third quarter 2025 financial results on Monday November 10, 2025, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate u ...

Core Viewpoint - Novartis plans to acquire U.S. biotech Avidity Biosciences for approximately $12 billion, which represents the company's largest acquisition under current leadership [1] Company Summary - The acquisition of Avidity Biosciences is a strategic move for Novartis, aiming to enhance its portfolio in the biotech sector [1] - Following the announcement, Novartis shares experienced a decline of 1% on Monday [1] Industry Summary - The acquisition highlights ongoing consolidation trends within the biotech industry, as larger pharmaceutical companies seek to expand their capabilities and product offerings through strategic purchases [1]

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Natera Inc. (NASDAQ: NTRA) breached their fiduciary duties to shareholders. If you currently own Natera stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal right. ...

Core Insights - IDEAYA Biosciences, Inc. is actively participating in investor relations events, showcasing its commitment to engaging with the investment community [1][3] - The company focuses on precision medicine in oncology, aiming to develop targeted therapies that are tailored to the genetic drivers of cancer [2] Group 1: Investor Relations Events - IDEAYA will participate in Citi's 2025 SMID Cap Biopharma Call Series on November 6, 2025, featuring a fireside chat with CEO Yujiro S. Hata [1] - The company will also be present at the Jefferies Global Healthcare Conference in London on November 18, 2025, with another fireside chat led by CEO Yujiro S. Hata [1] - Live audio webcasts of these events will be available on IDEAYA's website, with replays accessible for 30 days post-event [1] Group 2: Company Overview - IDEAYA is dedicated to the discovery, development, and commercialization of transformative cancer therapies [2] - The company integrates small-molecule drug discovery, structural biology, and bioinformatics to create targeted therapies [2] - IDEAYA has developed a robust pipeline focused on synthetic lethality and antibody-drug conjugates for specific solid tumor indications [2]

European stocks hovered near record levels on Monday, driven by optimism about easing U.S.-China trade tensions. Traders also looked ahead to a busy week of central bank announcements that includes rate decisions from the Federal Reserve, European Central Bank and the Bank of Japan.The U.S. central bank is widely expected to cut rates by 25 basis points, while the ECB and BOJ are expected to leave rates unchanged.On the earnings front, mega companies, including Apple Inc. and Microsoft Corp. while be unvei ...

Core Insights - Evotec SE has received a payment of US$ 25 million from Bristol Myers Squibb to support the progression of their joint programs focused on neurodegenerative diseases [1] Company Developments - The payment is intended to advance further research within the strategic neuroscience partnership between Evotec and Bristol Myers Squibb [1] - The collaboration aims to enhance the joint pipeline of programs targeting neurodegenerative diseases [1]

Market Overview - U.S. stocks experienced a significant rally, with major indices reaching all-time highs, driven by a softer-than-expected inflation reading that bolstered expectations for a 25 basis point interest rate cut by the Federal Reserve at its upcoming meeting on October 30 [1][4] Inflation Data - The annual headline inflation for September 2025 was reported at 3%, a slight increase from August's 2.9% but below the anticipated 3.1%. Core inflation, excluding food and energy, decreased from 3.1% to 3% year-over-year, indicating a cooler inflation environment [2] Company Performance - Ford Motor Co. emerged as the top-performing large-cap stock, surging 12% following the release of stronger-than-expected third-quarter earnings, marking its best session since 2022 [2] - In the small-cap sector, Inhibrx Biosciences Inc. saw a remarkable 102% increase in stock price after announcing positive trial results for its cancer drug ozekibart [3] Sector Performance - Most sectors within the S&P 500 closed positively, with information technology, communication services, and utilities showing the largest gains. Conversely, energy and materials sectors underperformed, closing lower [3] Index Readings - The CNN Money Fear and Greed Index recorded a reading of 33.1, remaining in the "Fear" zone, which indicates a slight increase from the previous reading of 28.6. This index reflects current market sentiment, with higher fear typically exerting downward pressure on stock prices [5]